Pelthos Therapeutics Inc (PTHS) Financial

Pelthos Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in North Brunswick, New Jersey and currently employs 4 full-time employees. The company went IPO on 2024-02-16. Pelthos Therapeutics Inc., formerly Channel Therapeutics Corporation, is a biopharmaceutical company focused on commercializing therapeutic products for high unmet patient needs. The firm's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. ZELSUVMI is an FDA-designated novel drug, and a prescription medication approved for the treatment of molluscum that can be administered at home by parents, patients, and caregivers. The firm is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.